Ovarian Cancer Intelligence — Updated August 2026

Ovarian Cancer in 2026:
Beyond "Chemo and Wait"

Ovarian cancer is no longer a single disease managed with paclitaxel and carboplatin. Today's decisions depend on five molecular layers: BRCA status, HRD score, FRα expression, platinum sensitivity, and CCNE1 amplification. This is a clinical decision engine — matching your tumor's biology to the exact maintenance strategy, PARP inhibitor, ADC trial, or HIPEC pathway across 7 countries.

💡 The 75% Reality Check — Why Ovarian Cancer Is Different: 75% of patients are diagnosed at Stage III or IV — not because screening failed, but because the disease spreads silently through the peritoneal cavity long before symptoms appear. But ovarian cancer is now the most biomarker-driven solid tumor in oncology. With BRCA/HRD testing, PARP maintenance, and FRα-targeted ADCs, we have moved from "6-month progression-free survival" to multi-year remissions in the right molecular subgroup.

5 Biomarkers SOLO-1 | PRIMA | MIRASOL Updated August 2026 $0 patient fees
The 5 Biomarkers Platinum Matrix Maintenance Engine
Molecular Precision

The 5 Critical Biomarkers That Determine Your Treatment

Ovarian cancer is now defined by its biology, not just its stage. These five biomarkers determine your treatment path.

BRCA1/BRCA2 Mutations

15-20% of ovarian cancers

Highest predictor of PARP inhibitor response. Olaparib maintenance in BRCA-mutated patients shows 56-month median PFS vs 14 months placebo (SOLO-1, 7-year follow-up).

Testing: Germline (blood) AND somatic (tumor) — 7% of mutations are somatic-only.

HRD (Homologous Recombination Deficiency)

50% of high-grade serous

Second most important biomarker. HRD-positive patients (BRCA-wildtype) still derive major benefit from PARP inhibitors — 37-month PFS vs 17 months (PRIMA trial with niraparib).

Scoring: MyChoice CDx (≥42 = HRD+), FoundationOne CDx (LOH score)

FRα (Folate Receptor Alpha)

70-80% express; 35-40% high-expressers

The 2024-2026 Breakthrough. Target for mirvetuximab soravtansine (Elahere) — FDA-approved 2024. ORR of 42% in heavily pretreated platinum-resistant patients.

Testing: VENTANA FOLR1 (RxDx) IHC assay — ≥75% viable tumor cells with ≥2+ staining.

CCNE1 Amplification

20% of high-grade serous

The PARPi Resistance Marker. CCNE1-amplified tumors do NOT respond to PARP maintenance. Identifies the 20% of patients who should not receive expensive PARP inhibitors.

Action: If CCNE1-amplified → consider ADC trials, WEE1 inhibitors, immunotherapy combinations.

TP53 Mutation

96% of high-grade serous

Near-universal driver mutation. Defines high-grade serous histology. While not directly targetable today, TP53 signature helps differentiate high-grade from low-grade serous — completely different treatment paradigms.

Role: Diagnostic marker, not currently targetable.

Critical Insight: Not getting tested for BRCA and HRD is now considered a clinical error. Request biomarker testing guidance →

The Most Important Classification

Platinum Sensitivity Classification Matrix

This is the single most important clinical classification in ovarian cancer management. It determines your entire salvage strategy at relapse.

Classification Platinum-Free Interval (PFI) Biological Meaning Salvage Strategy Best Country
Platinum-Refractory Progression DURING platinum Highly resistant, likely CCNE1-amplified FRα-ADC (mirvetuximab), clinical trials, WEE1 inhibitors 🇺🇸 USA, 🇨🇳 China
Platinum-Resistant <6 months Chemo-resistant, poor PARPi response Non-platinum chemo + bevacizumab, ADC trials, PARPi only if HRD+ 🇩🇪 Germany, 🇰🇷 Korea
Partially Platinum-Sensitive 6-12 months Intermediate biology Platinum rechallenge + bevacizumab, or PARPi maintenance if HRD+ 🇩🇪 Germany, 🇮🇳 India
Platinum-Sensitive >12 months Chemosensitive, PARPi-responsive Platinum rechallenge + PARPi maintenance Global standard
Platinum-Highly Sensitive >24 months Excellent prognosis Same as sensitive, longer maintenance PARPi justified Global standard

Critical Insight: PFI is a dynamic marker — it can change across relapses. A patient who was platinum-sensitive in first relapse may become platinum-resistant in second. Re-calculate PFI at every progression event.

The Most Important Decision

Maintenance Therapy Decision Engine

After first-line chemotherapy, this decision determines your next 2-4 years of progression-free survival.

First-Line Maintenance Decision Tree

START: Completed first-line platinum/taxane + achieved CR/PR
❓ BRCA1/2 mutated (germline or somatic)?
✅ YES → Olaparib maintenance (SOLO-1 protocol)
→ 56-month median PFS vs 14 months placebo
→ Duration: 2 years standard, some centers extend
❌ NO → Check HRD status
❓ HRD-Positive (MyChoice ≥42 or GIS-high)?
✅ YES → Niraparib maintenance (PRIMA protocol)
→ 37-month PFS vs 17 months → Or: Olaparib + Bevacizumab (PAOLA-1)
❌ NO (HRP) → Bevacizumab maintenance only (if started with chemo)
→ No proven PARPi benefit in HRP → Consider clinical trial (immune combinations, WEE1i)
Frontline PARPi Selection Guide:
Olaparib: BRCA-mutated, HRD+ | SOLO-1, PAOLA-1 | 2 years
Niraparib: All-comers (including HRP) | PRIMA | 3 years
Rucaparib: BRCA-mutated | ATHENA | 2 years
Veliparib: Research use | Trial only | N/A
Clinical Scenarios

Decision Trees: 4 Clinical Scenarios

Evidence-based decision pathways for the most common ovarian cancer scenarios.

🌳 Tree 1: Newly Diagnosed High-Grade Serous

  • Stage III, resectable, good PS? → Primary debulking surgery (aim R0)
  • Fagotti score <8 → direct surgery | ≥8 → NACT first
  • Stage IV, bulky, poor PS? → NACT (3 cycles) → IDS → 3 more cycles
  • Post-surgery: BRCA & HRD testing required → Apply Maintenance Engine
  • Consider HIPEC at IDS? → Stage III, complete cytoreduction achieved → HIPEC with cisplatin

🌳 Tree 2: Platinum-Sensitive First Relapse (PFI >6 months)

  • PFI >12 months? → Platinum doublet (carbo/gem or carbo/PLD) + bevacizumab → PARPi maintenance
  • PFI 6-12m? → Platinum doublet ± bevacizumab
  • Consider secondary cytoreduction (DESKTOP III criteria): Complete resection at first surgery ✓, PS 0, ascites <500ml ✓

🌳 Tree 3: Platinum-Resistant Relapse (PFI <6 months)

  • FRα IHC testing required immediately
  • FRα-high? → Mirvetuximab soravtansine (Elahere)
  • FRα-low/negative? → Single-agent chemo (PLD, topotecan, gemcitabine) ± bevacizumab
  • CCNE1-amplified? → WEE1 inhibitor trials (adavosertib), avoid PARPi

🌳 Tree 4: Third-Line and Beyond (Multi-Refractory)

  • Any targetable mutation? (NTRK, HER2, BRAF) → Matched targeted therapy
  • Eligible for CAR-T trial? → Targets: MUC16, mesothelin, FRα, CLDN6
  • Peritoneal-only disease, good PS? → PIPAC or pressurized intraperitoneal aerosol chemo
  • 🇨🇳 China: 100+ solid tumor CAR-T trials, $40K-$80K
The ADC Revolution

Mirvetuximab Soravtansine (Elahere) — The Game Changer

First successful antibody-drug conjugate in ovarian cancer in 20 years. Now moving to first-line trials.

Key Data (MIRASOL Phase III)

44.6%
ORR (vs 11.6% chemo)
16.5
Median OS (months) vs 11.8
5.6
Median PFS (months) vs 4.0
FRα+
High expression required
FDA Approval: November 2022 (accelerated), full approval 2024 | EU Approval: 2024

Next-Generation ADCs in Ovarian Cancer Trials (2025-2026)

SHR-A1811 — HER2/FRα | Phase 2/3 | 🇨🇳 China
STRO-002 (Luveltamab) — FRα | Phase 3 | 🇺🇸 USA, 🇪🇺
Upifitamab ralsodotec — MUC16 | Phase 3 | 🇺🇸 USA
Dato-DXd — TROP2 | Phase 2 | 🇯🇵 Japan, 🇺🇸 USA
Global Access

Country Logic by Biological Strength

Each country offers unique strengths for ovarian cancer treatment — from CAR-T trials to HIPEC expertise.

🇨🇳

China — CAR-T & Domestic PARPi Pioneer

100+ solid tumor CAR-T trials (MUC16, mesothelin, FRα, CLDN6). Domestic PARPi at 70-80% lower cost. Fast trial enrollment.

Explore China
🇩🇪

Germany — HIPEC & Surgical Excellence

World's highest-volume HIPEC centers (Charité, Heidelberg). DESKTOP III expertise. Full EMA PARPi portfolio.

Explore Germany
🇺🇸

USA — FRα-ADC Access & Novel Trials

Mirvetuximab (Elahere) — first to market. Latest ADC trials (Luvelta, STRO-002). MD Anderson, MSKCC programs.

Explore USA
🇰🇷

South Korea — Surgical Precision

JCI-accredited HIPEC programs. Robotic interval debulking surgery. Strong molecular pathology.

Explore South Korea
🇮🇳

India — Cost-Effective PARPi & Access

Generic olaparib, niraparib at 70% discount. High-volume surgical centers (Tata Memorial, Apollo).

Explore India
Questions

Frequently Asked Questions

Common questions about ovarian cancer treatment, biomarkers, and access.

BRCA1/2 testing (germline AND somatic) + HRD testing. These two tests determine whether you'll receive maintenance PARP inhibitors, which can extend progression-free survival by 2-4 years. Testing should be ordered at diagnosis, not at relapse.

BRCA is a specific gene mutation (15-20% of patients). HRD (Homologous Recombination Deficiency) is a broader functional state of DNA repair deficiency — present in 50% of high-grade serous patients. Some patients are BRCA-wildtype but HRD-positive — they still benefit from PARP inhibitors. Both tests are required.

Folate Receptor Alpha is a protein on ovarian cancer cells. In 2024, the FDA approved mirvetuximab soravtansine (Elahere) — an antibody-drug conjugate targeting FRα — for platinum-resistant, FRα-high ovarian cancer. This is the first successful ADC in ovarian cancer in 20 years. Testing requires the VENTANA FOLR1 assay.

Generally no. Clinical trials (SOLO-1, PRIMA, PAOLA-1) show PARPi benefits are concentrated in BRCA-mutated and HRD-positive patients. HRD-negative (HRP) patients derive minimal benefit, and the cost ($10K-$15K/month) and side effects may not justify use. Consider clinical trials instead.

HIPEC (Hyperthermic Intraperitoneal Chemotherapy) delivers heated chemotherapy directly into the abdomen during cytoreductive surgery. Best candidates: Stage III, complete cytoreduction achievable, good performance status, normal kidney function. Best offered at high-volume centers in Germany and South Korea.

This is "platinum-resistant" disease. First: test FRα expression. If FRα-high → mirvetuximab (Elahere). If FRα-low → non-platinum chemo ± bevacizumab, or clinical trials (ADC, CAR-T, WEE1 inhibitors). Check CCNE1 amplification — if present, avoid PARPi.

Cellular therapy trials — CAR-T targeting MUC16, mesothelin, FRα, or CLDN6. China has 100+ active solid tumor CAR-T trials. TIL therapy is emerging in the USA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal-only disease. FRα-ADC trials if not previously tried.

USA: $12K-$15K/month ($140K-$180K/year). Germany: €8K-€12K/month. India: Generic olaparib/niraparib at $2K-$4K/month (70% discount). China: Domestic PARPi (fluzoparib, pamiparib) at $1.5K-$3K/month. Duration: typically 2-3 years.

Continue Your Research

Related Decision Resources

China: CAR-T & Domestic PARPi

100+ solid tumor trials, fluzoparib access, next-gen FRα-ADCs.

View China Guide →

Germany: HIPEC & Surgical Precision

World-leading cytoreductive surgery, HIPEC programs, and DESKTOP III expertise.

View Germany Guide →

Cost Comparison

Real-world costs for PARPi, HIPEC, ADCs, and CAR-T across 7 countries.

View Cost Guide →

Submit Your Case

Free case assessment by gynecologic oncology specialists. 48-hour response.

Submit Now →

Ready to Match Your Ovarian Cancer to the Right Pathway?

Submit your pathology, BRCA/HRD results, and treatment history. Our gynecologic oncology team analyzes your molecular profile within 48 hours — identifying the optimal maintenance strategy, ADC trial, HIPEC center, or CAR-T pathway.

Submit Your Case — Free Assessment Explore Hospitals

Free • Confidential • 48-Hour Response • No Obligation • HIPAA-Aligned